Drug Profile
Salnacedin
Alternative Names: G 201Latest Information Update: 09 Mar 2015
Price :
$50
*
At a glance
- Originator Genta
- Developer Genta (CEASED)
- Class Anti-inflammatories; Antiacnes; Antipsoriatics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne; Dermatitis; Psoriasis
Most Recent Events
- 28 Aug 2001 Discontinued-II for Acne in USA (Topical)
- 28 Aug 2001 Discontinued-II for Dermatitis in USA (Topical)
- 28 Aug 2001 Discontinued-II for Psoriasis in USA (Topical)